胚胎干细胞来源的树突状细胞骨髓瘤疫苗抗瘤功能的观察

Function of anti-myeloma vaccine prepared by embryonic stem cell-derived dendritic cells

目的:探讨胚胎干细胞(ESC)来源的树突状细胞(DCs)骨髓瘤融合疫苗的抗肿瘤功能。方法:1)对骨髓瘤疫苗进行安全性检测,并观察其体外针对SP2/0的特异性细胞毒性T淋巴细胞(CTL)反应;2)融合疫苗的免疫保护实验和免疫治疗实验。结果:1)接种裸鼠未见致瘤情况初步证实该疫苗安全可靠,体外特异性CTL杀伤实验表明该融合疫苗具有较强的杀伤活性。2)ESC-DCs融合疫苗免疫组和BMC-DCs融合疫苗免疫组小鼠受到SP2/0攻击后,连续观察60d未见肿瘤形成。3)ESC-DCs融合疫苗治疗组小鼠中位生存时间为47d,BMC-DCs融合疫苗治疗组小鼠中位生存时间为46d,而PBS组小鼠中位生存时间仅为21d。结论:ESC-DCs与小鼠骨髓瘤细胞SP2/0融合制备得到的融合疫苗具有较强的抗肿瘤功能,与BMC-DCs来源的同类疫苗相比具有相似的生物学特性及功能性。

OBJECTIVE： To evaluate the anti-tumor functions of myelama vaccine prepared by embryonic stem cell-derived den dritic cells （ESC-DCs）. METHODS： 1 ）The safety evaluation of the vaccine in viw） and the specific cytotoxicity T lymphocyte reaction to aim directly at SP2/0 in vitro were performed. 2）The immunoprotection and immunotherapy experiments of fused vaccine were also performed. RESULTS： 1）The vaccine showed efficient a bility of provocating the SP2/0 specific CTI, reaction in vitro and were proved to be safety. 2）The mice vaccinated with ESC DCs derived or BMC-DCs-derived fused vaccine could resist the challenge of SP2/0 myeloma cells and survived for more than 60 days. 3） The survival curves were analysed and showed： the median survival time of the group treated with ESC-DCs derived fused vaccine was 47 days that were greatly extended to the control group with PBS which was 21 days, yet had no obvious superior to the BMC-DCs derived vaccine group which was 46 days. CONCLUSIONS： ESC DCs derived fused vaccine has the potentia to induce effectively anti-tumor immune responses. Compared with BMC-DCs derived fused vaccine, the myeloma vaccine has the similar bionomics and functions.